Zobrazeno 1 - 10
of 10
pro vyhledávání: '"M J, Troychak"'
Publikováno v:
The Prostate. 42(4)
A reliable imaging modality is required to uncover occult soft- tissue recurrence after failure of primary prostate cancer therapy. This retrospective study was done to evaluate the ability of the (111)Indium-labeled monoclonal antibody (ProstaScint(
Autor:
B A, Tjoa, S J, Simmons, A, Elgamal, M, Rogers, H, Ragde, G M, Kenny, M J, Troychak, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 40(2)
A phase II trial, involving infusions of autologous dendritic cells (DC) and two human histocompatibility antigen (HLA-A2)-specific prostate-specific membrane antigen (PSMA) peptides, was recently completed. Thirty percent of the participants, includ
Autor:
S J, Simmons, B A, Tjoa, M, Rogers, A, Elgamal, G M, Kenny, H, Ragde, M J, Troychak, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 39(4)
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF; Leukine [sargramostim], Immunex Corp., Seattle, WA) was administered to a subgroup of 44 patients in a phase II clinical trial for prostate cancer using DC pulsed with HLA-A2
Autor:
G P, Murphy, B A, Tjoa, S J, Simmons, H, Ragde, M, Rogers, A, Elgamal, G M, Kenny, M J, Troychak, M L, Salgaller, A L, Boynton
Publikováno v:
The Prostate. 39(1)
A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 and -P2). This report describes the evaluation of 37 subjects admitted with
Autor:
G P, Murphy, B A, Tjoa, S J, Simmons, J, Jarisch, V A, Bowes, H, Ragde, M, Rogers, A, Elgamal, G M, Kenny, O E, Cobb, R C, Ireton, M J, Troychak, M L, Salgaller, A L, Boynton
Publikováno v:
The Prostate. 38(1)
A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific PSMA peptides (PSM-P1 and -P2). This report describes thirty three subjects with hormone-refractory metastatic prostate cancer without
Publikováno v:
The Prostate. 37(4)
Primary extraprostatic spread or failure after prostate cancer treatment can occur locally in the prostatic fossa and/or metastasize to regional and/or distant lymphatics and/or in bone. We evaluated the ability of the ProstaScint (Cytogen Corp., Pri
Autor:
B A, Tjoa, S J, Simmons, V A, Bowes, H, Ragde, M, Rogers, A, Elgamal, G M, Kenny, O E, Cobb, R C, Ireton, M J, Troychak, M L, Salgaller, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 36(1)
A phase I trial involving patients with advanced prostate cancer was conducted to assess the safe administration of dendritic cells (DC) and HLA-A0201-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 or -P2). Thirty-three of the ph
Autor:
G P, Murphy, R T, Maguire, B, Rogers, A W, Partin, W B, Nelp, M J, Troychak, H, Ragde, G M, Kenny, R J, Barren, V A, Bowes, A K, Gregorakis, E H, Holmes, A L, Boynton
Publikováno v:
The Prostate. 33(4)
Stored serum from clinical trial cases undergoing ProstaScint (CYT-356) scanning were available for Prostate Specific Membrane Antigen (PSMA) assay. Prostate Specific Antigen (PSA) levels had already been determined. This provided an opportunity to s
Autor:
G P, Murphy, M J, Troychak, O E, Cobb, V A, Bowes, R J, Kenny, R J, Barren, G M, Kenny, H, Ragde, E H, Holmes, R L, Wolfert
Publikováno v:
The Prostate. 33(2)
Metastatic prostate cancer clinical evaluation is difficult. A revaluation of new prostate markers with regard to bone scans was performed.Serial markers, including bone alkaline phosphatase (BAP), total alkaline phosphatase (TAP), prostate-specific
Autor:
B A, Tjoa, S J, Erickson, V A, Bowes, H, Ragde, G M, Kenny, O E, Cobb, R C, Ireton, M J, Troychak, A L, Boynton, G P, Murphy
Publikováno v:
The Prostate. 32(4)
We recently conducted a phase I clinical trial administering autologous dendritic cells pulsed with prostate-specific membrane antigen (PSMA) peptides to advanced prostate cancer patients. Participants were divided into 5 groups receiving 4 or 5 infu